In response to the Advisory Actions of April 14, 2004 and March 15, 2004 in the above-identified application, please amend the application as follows:

IN THE SPECIFICATION

Page 1, lines 18-19, please insert the following:

X_1, X_2, X_3, X_4, same or different, are a group chosen among:

-CONR-, -NRCO-, -CH_2-NR-, -NR-CH_2- where R is H, C_{1-3} alkyl, or benzyl;

Page 1, lines 22-27, please insert the following:

-$(CH_2)_r$ Ar where r is 0, 1 or 2 and Ar is an aromatic group chosen among benzene, naphthalene, thiophene, benzothiophene, pyridine, quinoline, indole, furan, benzofuran, thiazole, benzothiazole, imidazole, benzoimidazole, possibly substituted with up to 2 substituents chosen among C_{1-3} alkyl, C_{1-3} haloalkyl, C_{1-3} alkyloxy [and], C_{2-4} amino-alkyloxy, halogen, OH, NH_2, CN, and NR_6R_7 , where R_6 and R_7, are the same or different, and are H or C_{1-3} alkyl,

Page 1, lines 29-32, please insert the following:

-$(CH_2)_rAr_1$ where r is 0, 1, or 2 and Ar_1 is an aromatic group chosen among: ben[e]zene, naphthalene, thiophene, benzothiophene, pyridine, quinoline, indole, furan, benzofuran, thiazole, benzothiazole, imidazole, benzoimidazole, possibly substituted with up to 2 groups chosen among: C_{1-3} alkyl, C_{1-3} haloalkyl, C_{1-3} alkyloxy, C_{2-4} amino-alkyloxy, halogens, OH, NH_2, CN, and NR_6R_7, where R_6 and R_7 are the same or different, and are H or C_{1-3} alkyl;

At page 5, lines 15-20, please insert:

R_9 is a group chosen among: 4-tetrahydropyranyl, ~~4-tetraiodothiopyranyl~~ 4-tetrahydrothiopyranyl, ~~1-oxotetraiodothiopyran-4-yl~~

1-oxotetrahydrothiopyran-4-yl,1,1 dioxo-tetrahydrothiopyran-4-yl, N-methyl-4-piperidinyl, N-methanesulfonyl-4-piperidinyl, N-aminosulfonyl-4-piperdinyl, or R_8 and R_9 together with the N atom to which they are linked represent N-methyl-piperazinyl, N-acetyl-piperazinyl, piperazinyl, N-methanesulfonyl-piperazinyl.

At page 6, lines 13-18, please insert:

xii) cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Phe(4-CF[3]$_3$)-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

xiii) cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Ala(4-pyridyl)-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

xiv) cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Ala(3-pyridyl)-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

Page 7, lines 1-5, please insert:

Among the compounds of formula (I) wherein R, R[1]$_1$, R[2]$_2$, R[3]$_3$, f, m are as hereabove defined preferred are also those wherein:

R_4 represents a group NR_8R_9, where R_8 is H and R[9]$_9$ is chosen among: methanesulfonyl, tosyl, a group (CH[2]$_2$)[g]$_g$-R_{10} wherein g is 1[,] or 2 and R_{10} is chosen among: morpholine, furan, or CN.

Page 7, lines 23-29, please insert:

Another preferred selection of the compound of formula (I) wherein R, R[1]$_1$, R[2]$_2$, R[3]$_3$, f, m are as previously defined, those wherein:

R[4]$_4$ represents a group -N(R_{11})CO(CH_2)$_h$-R_{12} wherein R_{11} is H, h is 0 or 1, and R[12]$_{12}$ is chosen among: 1-tetrazolyl, 5-mercapto-tetrazol-1-yl, 1-triazolyl, furanyl,

thiophenyl, morpholine, 4-hydroxy-piperidine, 4-carboxyamido-piperidine, 3-hydroxy-pyrrolidine,

2-hydroxymethylpyrrolidine, 4-methyl-piperazine, 4-aminosulfonyl-piperazine, 1-oxo-thiomorpholine, 4-hydroxy-cyclohexan-1-yl-amino.

At page 9, lines 7-8, please insert:

Another preferred selection of compounds of formula (I) wherein R, $R[1]_1$, $R[2]_2$, $R[3]_3$, f, m are as above defined are those wherein:

At page 9, lines 9-10, please insert:

$R[4]_4$ is a group COR_{13} where R_{13} is a group chosen among: morpholine and 4-(hydroxyethyloxyethyl)-piperazine.

At page 10, lines 26-31, please insert:

EXAMPLE 1: cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Phe-[(R)-NH-$CH(CH_2-C_6H_5)-CH_2NH$]}

(compound of general formula I wherein $X_1 = X_2 = X[3]_3 = X_4$ = -CO-NH-; R_1 = $-CH_2$-(indol-3-yl); $R_2 = R_3 = -CH_2-C_6H_5$; $R[4]_4$, = (4-tetrahydropyranyl)amino; m = 0, f = 1; the carbon atoms C-R_1 and C-R_2 have configuration S, while C-R_3 and C-R_4 have configuration R).

At page 11, lines 2-5, please insert:

(compound of formula (I) wherein: $X_1 = X_2 = X[3]_3 = X_4$ = -CO-NH-; $R_1 = -CH_2$-(indol-3-yl); $R_2 = R_3 = -CH_2-C_6H_5$; $R_4 = -NH_2$; m = 0, f = 1; the carbon atoms C-R_1 and C-R_2 have configuration S, while C-R_3 and C-R_4 have configuration R) is used. The compound A is prepared as follows:

At page 11, lines 24-30, please insert:

c) Synthesis of Boc-Trp-Phe-[(R)-NH-CH(CH[2]$_2$-C_6H_5)-CH_2-NH-Z]

To a solution of Boc-Trp-Phe-OH (1.19 g, 2.63 mmoli) in anhydrous DMF (10 ml) (R)-1-benzyl-2-(benzyloxycarbonylamino)ethylamine (750 mg), PyBOP (1.37 g) e DIEA (0.9 ml) were added under nitrogen. The reaction mixture was left under stirring for a night at room, added with AcOEt (80 ml), washed with HCl 1N (3 x 30 ml), Na_2CO_3 5% (3 x 30 ml) and H_2O (30 ml). The organic phase was evaporated under vacuum at 30°C, giving 1.8 g of ivory colored solid residue.

At page 14, lines 9-13, please insert:

EXAMPLE 2: cyclo{Suc[1-(S)-(4-tetrahydropyranyl)amino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

(compound of general formula (I) wherein C-R[4]$_4$ has S configuration, R[4]$_4$ is (4-tetrahydropyranyl)amino and the other substituents are as described for Compound A).

At page 14, lines 18-23, please insert:

EXAMPLE 3: cyclo{Suc[1-(R)-(1-methyl-piperidin-4-yl)amino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

(compound of general formula I wherein R[4]$_4$ is (1-methyl-piperidin-4-yl)amino and the other substituents are as described for Compound A.

The compound is prepared as in example 1 but using as reagent 1-methyl-4-piperidone.

At page 15, lines 2-6, please insert:

(compound of formula I wherein R[4]$_4$ is (4-tetrahydrothiopyranyl)amino and the other substituents are as described for compound A).

The compound is prepared according to Example 1 but using as reagent tetrahydro-thiopyran-4-one.

At page 15, lines 7-11, please insert:

EXAMPLE 5: cyclo{Suc[1-(R)-(1-oxo-tetrahydrothiopyran-4-yl)amino]-Trp-Phe-[(R)NH-CH(CH_2-C_6H_5)-CH_2NH]}

(compound of general formula I wherein $R[4]_4$ is (1-oxo-4-tetrahydrothiopyranyl)amino and the other substituents are the same of Compound A).

At page 15, lines 16-20, please insert:

EXAMPLE 6: cyclo{Suc[1-(R)-(1,1-dioxo-tetrahydrothiopyran-4-yl)amino]-Trp-Phe[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

(compound of general formula I wherein $R[4]_4$ is (1,1-dioxo-4-tetrahydrothiopyranil)amino and the other substituents are the same of Compound A).

At page 15, lines 25-29, please insert:

EXAMPLE 7: cyclo{Suc[1-(R)-N-methyl-N-(4-tetrahydropyranyl)amino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

(compound of general formula I wherein $R[4]_4$ is N-methyl-N-(4-tetrahydropyranyl)amino and the other substituents are the same of Compound A).

At page 16, lines 8-12, please insert:

EXAMPLE 8: cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Tyr-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

(compound of general formula I wherein [cui] R_2 = 4-hydroxybenzyl, $R[4]_4$ =(4-tetrahydropyranyl)amino and the other substituents are as defined for Compound A).

At page 16, lines 17-21, please insert:

EXAMPLE 9: cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Phe(4-F)-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

(compound of general formula I wherein [cui] R_2 =4-fluorobenzyl, $R[4]_4$ =(4-tetrahydropyranyl)amino and the other substituents are as defined for Compound A).

At page 16, lines 26-30, please insert:

EXAMPLE 10: cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Phe(3,5-F)-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

(compound of general formula I wherein [cui] R_2 = 3,5-difluorobenzyl, $R[4]_4$ =(4-tetrahydropyranyl)amino and the other substituents are as defined for Compound A).

At page 17, lines 5-14, please insert:

EXAMPLE 11: cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Phe(4-CN)-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

To 377 mg of Boc-(S)-4-ciano-phenylalanine, solved in 8 ml of DMF, HOBt (470 mg), EDCI.HCl (330 mg) and 630 mg of (R)-1-benzyl-2-(N-fluorenylmethyloxycarbonylamino)ethylamina trifluoroacetate (prepared according to Example 1(b)), solved in 8 ml of DMF are added in the given order. DIEA (0.38 ml) is added drop by drop maintaining under stirring for 3 h. The solution is dried and the residue is treated with citric acid 105 and water; the precipitated solid is filtered, washed with water, $NaHCO[3]_3$ 5%, water and dried. The obtained solid (790 mg) is suspended in dichlorometane (6.5 ml).

At page 18, lines 26-29, please insert:

EXAMPLE 12: cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Phe(4-$CF[3]_3$)-[(R)-NH-$CH(CH_2$-$C_6H_5)$-CH_2NH]}

(compound of formula I wherein R_2 = (4-trifluoromethyl)benzyl, $R[4]_4$ =(4-tetrahydropyranyl)amino and the other substituents are as in Compound A.

At page 19, lines 3-9, please insert:

EXAMPLE 13: cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Ala(4-pyridyl)-[(R)-NH-$CH(CH_2$-$C_6H_5)$-CH_2NH]}

(compound of formula I wherein R_2 = 4-pyridylmethyl, $R[4]_4$ =(4-tetrahydropyranyl)amino and the other substituents are as in Compound A.

At page 19, lines 11-14, please insert:

EXAMPLE 14: cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Ala(3-pyridyl)-[(R)-NH-$CH(CH_2$-$C_6H_5)$-CH_2NH]}

(compound of general formula I wherein R_2 = 3-pyridylmethyl, $R[4]_4$ = (4-tetrahydropyranyl) and the other substituents are as in Compound A.

At page 19, lines 19-24, please insert:

EXAMPLE 15: cyclo{Suc[1-(R)-(1-methylsulfonyl-piperidin-4-yl)amino]-Trp-Phe-[(R)-NH-$CH(CH_2$-$C_6H_5)$-CH_2NH]}

(compound of formula I wherein $R[4]_4$ = (1-methylsulfonyl)piperidin-4-yl)amino and the other substituents are as in Compound A).

At page 19, lines 27-30, please insert:

EXAMPLE 16: cyclo{Suc[1-(R)-(1-aminosulfonyl-piperidin-4-yl)amino]-Trp-Phe-[(R)-NH-$CH(CH_2$-$C_6H_5)$-CH_2NH]}

(compound of general formula I wherein $R[4]_4$ = (1-aminosulfonyl)piperidin-4-yl)amino and the other substituents are as in Compound A).

At page 20, lines 5-8, please insert:

EXAMPLE 17: cyclo{Suc[1-(R)-(piperazin-1-yl)]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

(compound of formula I wherein $R[4]_4$ = piperazin-1-yl and the other substituents are as in Compound A.

At page 20, lines 20-23, please insert:

EXAMPLE 18: cyclo{Suc[1-(R)-4-methyl-piperazin-1-yl]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

(compound of formula I wherein $R[4]_4$ = 4-methyl-piperazin-1-yl and the other substituents are as described in Compound A)

At page 21, lines 2-5, please insert:

EXAMPLE 19: cyclo{Suc[1-(R)-4-acetyl-piperazin-1-yl]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

(compound of general formula I wherein $R[4]_4$ = 4-acetyl-piperazin-1-yl and the other substituents are as described in Compound A)

At page 21, lines 15-18, please insert:

EXAMPLE 20: cyclo{Suc[1-(R)-(4-methanesulfonyl-piperazin-1-yl)]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

(compound of general formula I wherein $R[4]_4$ = 4-methanesulfonyl-piperazin-1-yl and the other substituents are as described in Compound A).

At page 21, lines 28-31, please insert:

EXAMPLE 21: cyclo{-Suc[1-(S)-methanesulfonylamino]-Trp-Phe-[(R)-NH-$CH(CH_2C_6H_5)$-CH_2-NH]}

(compound of general formula I wherein C-$R[4]_4$ has S-configuration, $R[4]_4$ is methanesulfonylamino and the other substituents are as described in compound A)

At page 22, lines 1-8, please insert:

To a solution of 60 mg of the isomer of Compound A having S-configuration at the C-$R[4]_4$, prepared as described in Example 1(a)-1(h), in 1 ml DMF, at 0°C, 24 ml of N-methylmorpholine and 10 ml of methanesulfonylchloride are added; the solution is left under stirring for 2 and half h. The reaction mixture is concentrated under vacuum, diluted with ethylacetate and washed with an aqueous solution of citric acid (10%), water, saturated solution of $NaHCO_3$ and water in the given order. After drying on Na_2SO_4 and evaporation of the solvent the product is isolated by preparative HPLC.

At page 22, lines 16-19, please insert:

EXAMPLE 22: cyclo{Suc[1-(R)-methanesulfonylamino]-Trp-Phe-[(R)-NH-$CH(CH_2$-$C_6H_5)$-CH_2NH]}

(compound of general formula I wherein $R[4]_4$ is methanesulfonylamino and the other substituents are as described for Compound A)

At page 22, lines 25-31, please insert:

EXAMPLE 23: cyclo{Suc[1-(S)-(4-methylbenzen)sulfonylamino]-Trp-Phe-[(R)-NH-$CH(CH_2$-$C_6H_5)$-CH_2NH]}

(compound of general formula I wherein C-$R[4]_4$ has S-configuration, $R[4]_4$ is (4-methylbenzen)sulfonylamino and the other substituents are as described for Compound A)

At page 22, lines 30-31, please insert:

As starting compound the isomer of Compound A having S-configuration at the C-R[4]$_4$ is used.

At page 23, lines 2-6, please insert:

EXAMPLE 24: cyclo{Suc[1-(R)-(4-methylbenzen)solfonylamino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

(compound of formula I wherein R[4]$_4$ is (4-methylbenzen)sulfonylamino and the other substituents are as described for Compound A)

At page 23, lines 11-15, please insert:

EXAMPLE 25: cyclo{Suc[1-(S)-(2-(4-morpholino)ethylamino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

(compound of general formula I wherein C-R[4]$_4$ has S-configuration, R[4]$_4$ is 2-(4-morpholino)ethylamino and the other substituents are as described for Compound A)

At page 23, lines 26-29, please insert:

EXAMPLE 26: cyclo{Suc[1-(R)-(2-(4-morpholino)ethylamino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

(compound of general formula I wherein R[4]$_4$ is 2-(4-morpholino)ethylamino and the other substituents are as described for Compound A)

At page 24, lines 2-5, please insert:

EXAMPLE 27: cyclo{Suc[1-(R)-(2-furylmethyl)amino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

(compound of formula I wherein R[4]$_4$ is (2-furylmethyl)amino and the other substituents are as described for Compound A)

At page 24, lines 15-18, please insert:

EXAMPLE 28: cyclo{Suc[1-(R)-c[i]yanomethylamino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

compound of general formula I wherein R[4]$_4$ is c[i]yanomethylamino and the other substituents are as described for Compound A)

At page 25, lines 1-2, please insert:

(compound of general formula I wherein R[4]$_4$ is 2-(4-morpholinoacetyl)amino and the other substituents are as described for Compound A)

At page 25, lines 16-20, please insert:

EXAMPLE 30: cyclo{Suc[1-(S)-2-(4-morpholinoacetyl)amino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

(compound of general formula I wherein R[4]$_4$ is 2-(4-morpholinoacetyl)amino, C-R[4]$_4$ has S-configuration and the other substituents are as described for Compound A)

At page 25, lines 28-32, please insert:

EXAMPLE 31: cyclo{Suc[1-(S)-(2-tetrazol-1-yl)acetylamino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

(compound of general formula I wherein C-R[4]$_4$ has S-configuration, R[4]$_4$ is (2-tetrazol-1-yl)acetylamino and the other substituents are as described for Compound A)

At page 26, lines 1-2, please insert:

As starting compound the isomer of compound A having S-configuration at C-R[4]$_4$ is used.

At page 26, lines 8-11, please insert:

EXAMPLE 32: cyclo{Suc[1-(R)-(2-tetrazol-1-yl)acetylamino]-Trp-Phe-[(R)-NH-$CH(CH_2\text{-}C_6H_5)\text{-}CH_2NH$]}

(compound of general formula I wherein $R[4]_4$ is (2-tetrazol-1-yl)acetylamino and the other substituents are as described for Compound A)

At page 26, lines 13-17, please insert:

EXAMPLE 33: cyclo{Suc[1-(S)-(2-(5-mercapto-tetrazol-1-yl)acetylamino]-Trp-Phe-[(R)-NH-$CH(CH_2\text{-}C_6H_5)\text{-}CH_2NH$]}

(compound of general formula I wherein C-$R[4]_4$ has S-configuration, $R[4]_4$ is (2-(5-mercapto-tetrazol-1-yl)acetylamino and the other substituents are as described for Compound A)

At page 26, lines 18-19, please insert:

As starting compound the isomer of Compound A having S-configuration at C-$R[4]_4$ is used.

At page 26, lines 25-29, please insert:

EXAMPLE 34: cyclo{Suc[1-(R)-2-([1,2,4]triazol-1-yl)acetylamino]-Trp-Phe-[(R)-NH-$CH(CH_2\text{-}C_6H_5)\text{-}CH_2NH$]}

(compound of general formula I wherein $R[4]_4$ is 2-([1,2,4]triazol-1-yl)acetylamino and the other substituents are as described for Compound A)

At page 27, lines 1-4, please insert:

EXAMPLE 35: cyclo{Suc[1-(R)- (furan-2-yl)carbonylamino]-Trp-Phe-[(R)-NH-$CH(CH_2\text{-}C_6H_5)\text{-}CH_2NH$]}

(compound of general formula I wherein $R[4]_4$ is (furan-2-yl)carbonylamino and the other substituents are as described for Compound A)

At page 27, lines 10-13, please insert:

EXAMPLE 36: cyclo{Suc[1-(R)-2-(thiophen-3-yl)acetylamino]-Trp-Phe-[(R)-NH-$CH(CH_2-C_6H_5)-CH_2NH$]}

(compound of general formula I wherein $R[4]_4$ is 2-(thiophen-3-yl)acetylamino and the other substituents are as described for Compound A)

At page 27, lines 18-21, please insert:

EXAMPLE 37: cyclo{Suc[1-(R)-(4-morpholino)carbonylamino]-Trp-Phe-[(R)-NH-$CH(CH_2-C_6H_5)-CH_2NH$]}

(compound of general formula I wherein $R[4]_4$ is (4-morpholino)carbonylamino and the other substituents are as described for Compound A)

At page 27, lines 29-31, bridging page 28 line 1, please insert:

EXAMPLE 38: cyclo{Suc[1-(R)-2-(4-hydroxy-piperidin-1-yl)acetylamino]-Trp-Phe-[(R)-NH-$CH(CH_2-C_6H_5)-CH_2NH$]}

(compound of general formula I wherein $R[4]_4$ is 2-(4-hydroxy-piperidin-1-yl)acetylamino and the other substituents are as described for Compound A)

At page 28, lines 6-10, please insert:

EXAMPLE 39: cyclo{Suc[1-(R)-2-(4-aminocarbonyl-piperidin-1-yl)acetylamino]-Trp-Phe-[(R)-NH-$CH(CH_2-C_6H_5)-CH_2NH$]}

[(R)-NH-$CH(CH_2-C_6H_5)-CH_2NH$]}

(compound of general formula I wherein $R[4]_4$ is 2-(4-aminocarboniy-piperidin-1-yl)acetylamino and the other substituents are as described for Compound A)

At page 28, lines 15-20, please insert:

EXAMPLE 40: cyclo{Suc[1-(R)-2-(3-hydroxy-pyrrolidin-1-yl)acetylamino]-Trp-Phe-[(R)-NH-$CH(CH_2-C_6H_5)-CH_2NH$]}

(compound of general formula I wherein $R[4]_4$ is 2-(3-hydroxy-pyrrolidin-1-yl)acetylamino and the other substituents are as described for Compound A)

At page 29, lines 2-3, please insert:

(compound of general formula I wherein $R[4]_4$ is 2-(4-methyl-piperazin-1-yl)acetylamino and the other substituents are as described for Compound A)

At page 29, lines 8-19 and 20-27, please insert:

EXAMPLE 43: cyclo{Suc[1-(R)-2-(4-methyl-piperazin-1-yl)carbonylamino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

(compound of general formula I wherein $R[4]_4$ is 2-(4-methyl-piperazin-1-yl)carbonylamino and the other substituents are as described for Compound A)

A solution of 40 mg of compound A, obtained as described in EXAMPLE 1(a)-1(h), and 400 µl of DIPEA in THF (0.5 ml), is added, under nitrogen, to a solution of 27 mg of 4-methyl-1-piperazinocarbonyl chloride (prepared as described in C. Jorand-Lebrun et al., Synth. Commun. (1998), 28, 1189) in 0.5 ml of dichloromethane. The solution is stirred for 2 h at room temperature, dried and purified by HPLC (Method P7).

HPLC (Method A2): rt =11.8 min.

MS: m/z = 707.2 (MH^+).

EXAMPLE 44: cyclo{Suc[1-(R)-2-(4-aminosulfonyl-piperazin-1-yl)acetylamino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

(compound of general formula I wherein $R[4]_4$ is 2-(4-aminosulfonyl-piperazin-1-yl)acetylamino and the other substituents are as described for Compound A)

The compound was prepared according to EXAMPLE 29 but using as reagent 2-(4-aminosulfonyl-piperazin-1-yl)acetic acid.

HPLC (Method A2): rt =12.5 min.

MS: m/z = 786.3 (MH^+)

At page 29, lines 26-31, please insert:

EXAMPLE 45: cyclo{Suc[1-(R)-2-(1-oxo-thiomorpholin-4-yl)acetylamino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

(compound of general formula I wherein R[4]$_4$ is 2-(1-oxo-thiomorpholin-4-yl)acetylamino and the other substituents are as described for Compound A)

At page 30, lines 5-9, please insert:

EXAMPLE 46: cyclo{Suc[1-(R)-2-*(trans*-4-hydroxy-cyclohexan-1-yl-amino)acetylamino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

(compound of general formula I wherein R[4]$_4$ is 2-*(trans*-4-hydroxy-cyclohexan-1-yl-amino)acetylamino and the other substituents are as described for Compound A).

At page 30, lines 14-19, please insert:

EXAMPLE 47: cyclo{Suc[1-(4-morpholino)carbonyl]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

(compound of general formula I wherein : $X_1 = X_2 = X3 = X_4$ = -CO-NH-; R_1 = -CH_2-(indol-3-yl); $R_2 = R_3$ = -CH_2-C_6H_5; R[4]$_4$ = (4-morpholino)carbonyl; m = 0, f = 1; the C-R_1 and C-R_2 carbon atoms have S-configuration, while C-R_3 has R-configuration)

At page 31, lines 21-28, please insert:

To a solution of 200 mg of H-Trp-Phe-{(R)-NH-CH(CH_2-C_6H_5)-CH_2-NH-[2-(4-nitro-benzyloxycarbonyl)]-1-succinic acid in DMF (10 ml), under nitrogen at 0°C, PyBOP (160 mg) and TEA (108 µl) were added; the solution was left under stirring at room temperature for 2 hours and thereafter sampled by HPLC. The solvent was evaporated and the residue was solved in ethylacetate. The organic phase was washed with

KHSO[4]$_4$ aq. 5%, NaHCO3 aq. 5%, brine and was dried on anhydrous sodium sulfate. After filtration and evaporation of the solvent 180 mg of a residue were obtained.

At page 32, lines 4-9, please insert:

The compound cyclo{Suc[1-(4-nitro-benzyloxycarbonyl)-Trp-Phe-[(R)NH-CH(CH_2-C_6H_5)-CH_2-NH]} "slow moving" (50 mg) was added to a mixture 1:1 of water/isopropanole (2 ml) containing K[2]$_2$CO[3]$_3$ (17 mg). The reaction mixture was reacted for 24 h at room temperature, concentrated, diluted with water and extracted with ethylacetate to eliminate the unreacted product.

At page 32, lines 19-27, please insert:

The compound cyclo {Suc[1-(4-nitro-benzyloxycarbonyl)-Trp-Phe-[(R)-NH-CH_2-C_6H_5)-CH_2-NH]} "slow moving" (50 mg) was added to a mixture 1:1 of water/isopropanole (2 ml) containing K[2]$_2$CO[3]$_3$ (17 mg). The reaction mixture was extracted with ethylacetate to eliminate the unreacted product. The aqueous phase was acidified with HCl 1N up to the formation of a white suspension and extracted with ethylcetate. The organic phase of the second extraction was dried on anhydrous sodium sulfate and evaporated to give 18 mg of a white solid. The product was purified by preparative HPLC (Method P8).

At page 33, lines 13-17, please insert:

EXAMPLE 48: cyclo{Suc[1-(4-hydroxyethyloxyethyl-piperazin-1-yl)carbonyl]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

(compound of general formula I wherein R[4]$_4$ is (4-hydroxyethyloxyethyl-piperazin-1-yl)carbonyl and the other substituents are as described in EXAMPLE 47)

HPLC (Method A2): rt =11.9 min.